Sequana Medical NV: Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON

PRESS RELEASEREGULATED INFORMATION - INSIDE INFORMATION15 November 2022, 07:00 am CET Data from SAHARA with first-generation DSR product (DSR 1.0) confirm: Safe, effective and rapid

Related Keywords

Canada ,China ,Mexico ,United States ,Hong Kong ,United Kingdom ,Belgium ,American ,Jeffrey Testani ,Mary Clark ,Nick Bastin ,Strategic Communications ,Professor At Yale University ,York Heart Association ,Company Or Sequanamedical ,Data Monitoring Committee ,Seattle Heart Failure ,Jefferies Healthcare Conference ,Euronext Brussels ,Direct Sodium Removal ,Associate Professor ,Yale University ,Heart Failure Scientific Advisor ,Sequana Medical ,Chief Medical Officer ,North American ,Pre Market Approval ,Investigational New ,Glomerular Filtration Rate ,New York Heart Association ,Seattle Heart Failure Model ,Safety Monitoring ,Sequana ,Medical ,Nnounces ,Positive ,Line ,Results ,Rom ,Sahara ,Study ,Diuretic ,Resistant ,Heart ,Failure ,Patients ,Persistent ,Congestion ,First ,Patient ,Hosed ,Uccessfully ,Yukon ,